Plasma is a liquid portion of blood. About 55% of the blood is plasma, and remaining 45% are red blood cells, white blood cells, and platelets that are suspended in the plasma. Products made from human plasma using plasma fractionation techniques are known as plasma derivatives. These are used in the treatment of various life threatening diseases.
Market Dynamics:
Rise in burden of genetic diseases, increasing geriatric population, high demand for blood plasma derivatives, growing use of immunoglobulins in various therapeutic areas, and increasing number of plasma collection centres are major factors expected to augment the growth of the global blood plasma derivatives market during the forecast period.
For instance, in March 2022, Sanofi SA and IGM Biosciences, Inc. collaborated to create, develop, manufacture, and commercialize immunoglobulin (IgM) antibody agonists against three oncology and immunology/inflammation targets. Engineered antibodies represent a new class of potential therapeutics that combine the multi-valency of antibodies possessing 10 binding sites compared to conventional IgG antibodies having only 2 target binding sites.
Key features of the study:
- This report provides in-depth analysis of the global blood plasma derivatives market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global blood plasma derivatives market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Shire Plc., CSL Limited, Octapharma AG, LFB S.A., Biotest AG, Grifols, S.A., SK Plasma Co., Ltd., Baxter International Inc., Green Cross Corporation, and Fusion Health Care Pvt. Ltd., among others.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global blood plasma derivatives market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global blood plasma derivatives market.
Detailed Segmentation:
- Global Blood Plasma Derivatives Market, By Type:
- Albumin
- Factor VIII
- Factor IX
- Immunoglobulin
- Hyperimmune Globulin
- Other
- Global Blood Plasma Derivatives Market, By Application:
- Hemophilia
- Hypogammaglobulinemia
- Immunodeficiency Diseases
- Von Willebrand' disease (VWD)
- Other Application
- Global Blood Plasma Derivatives Market, By Geography:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
- Company Profiles:
- Shire Plc.
- CSL Limited
- Octapharma AG
- LFB S.A.
- Biotest AG
- Grifols, S.A.
- SK Plasma Co., Ltd.
- Baxter International Inc.,
- Green Cross Corporation
- Fusion Health Care Pvt. Ltd.
